CION Ameerpet
Prognosis Guide · Reviewed by CION Oncologists · NABH Accredited
Cervical Cancer Survival by Stage — What the Numbers Really Mean
If you have just been given a stage, the first thing you probably did was search for a percentage. It is worth knowing before you go further that a survival statistic describes a group of women treated in the past — it is not a prediction about you. Stage is the strongest single influence on outcome in cervical cancer, which is why the figures are grouped by it. But two women with the same stage can have very different outlooks depending on tumour size, lymph nodes, subtype, general health and whether their treatment is completed on schedule. This page explains what the numbers measure, what moves them, and how to have the conversation properly with an oncologist at CION's 7 NABH-accredited Hyderabad locations.
- Stage matters most — outcomes are consistently best when disease is still confined to the cervix
- Published figures are historical — they describe women treated years ago, before today's imaging and radiation technique
- Where you are treated shows up in the data — completing radiation on time and running every case past a tumour board changes results
- Your own numbers exist — ask your oncologist what your specific stage, size and node status mean, with your reports in hand
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
What a Survival Rate Actually Measures
A five-year survival rate is a simple count: of a large group of women diagnosed at a particular stage some years ago, what proportion were still alive five years later. Four things follow from that definition, and each of them matters when you apply the number to yourself.
- It looks backwards, not forwards. To report five-year survival, a registry needs women diagnosed at least five years ago — usually longer. Those women were staged with older imaging and treated with older radiation technique. The figure you read today describes a standard of care that has since moved on.
- It is an average of a wide range. Within any one stage, some women had small tumours and clear nodes and others had bulky disease. A single percentage flattens that range into one number, and you are somewhere inside the range, not at the average point.
- “Five-year survival” is not the same as “five years to live”. It is a measuring post chosen because most recurrences appear well before it. Women counted as survivors at five years are, in the great majority, simply living on.
- Relative survival adjusts for other causes of death. Many published figures are relative rather than absolute, meaning they compare women with the cancer to women of the same age without it. This is a fairer measure of the cancer's effect, but it makes raw comparison between two sources unreliable.
This is why CION does not print a table of per-stage percentages on this page. Registry figures differ by country, by era and by how completely nodes were assessed, and quoting one of them next to your stage would give an impression of precision that the data does not support. What we can do — and what an appointment is for — is read your own staging scans, pathology and node status and tell you what they mean.
Did You Know? FIGO revised cervical cancer staging in 2018, and the change matters when you read older statistics. Imaging and pathology findings were formally allowed into the stage for the first time, and a new stage IIIC was created for disease with involved pelvic or para-aortic lymph nodes regardless of tumour size. A woman who would once have been called stage IB is now stage IIIC if her nodes are positive — so survival tables published before and after 2018 are not describing the same groups. Source: FIGO revised staging for carcinoma of the cervix uteri (2018).
Stage by Stage — What Each One Describes
Understanding what the stage is describing anatomically explains, better than any percentage can, why the outlook differs between them. The full definitions are on our guide to FIGO staging for cervical cancer.
Stage IA
Microscopic Disease Only
Invasion visible only under the microscope, measured in millimetres of depth. It is found on a cone biopsy or after treatment for precancer, not by examination. Outcomes at this stage are excellent, and for the smallest lesions fertility-sparing surgery can often be considered.
Stage IB
Confined to the Cervix, Visible
A tumour that can be seen or measured, still limited to the cervix. Sub-divided by size, because size drives both the treatment choice and the outlook. Most women here are treated with surgery, or with chemoradiation where the tumour is bulky.
Stage II
Beyond the Uterus
The disease has extended into the upper vagina or into the parametrium, but has not reached the pelvic sidewall or the lower third of the vagina. Chemoradiation, including brachytherapy, becomes the usual backbone of treatment rather than surgery.
Stage III
Pelvic Sidewall, Lower Vagina or Nodes
Disease reaching the lower vagina or the pelvic sidewall, causing obstruction of a kidney, or involving pelvic or para-aortic lymph nodes (stage IIIC). Still treated with intent to control the disease, but the radiation field and the systemic component are larger.
Stage IVA
Bladder or Rectum Involved
The tumour has grown into the lining of the bladder or the rectum but has not spread to distant organs. Treatment is usually chemoradiation, sometimes with a surgical option considered in highly selected cases.
Stage IVB
Distant Spread
Disease outside the pelvis — distant nodes, lungs, liver or bone. Systemic therapy leads, with radiation used for symptom control. Our page on living with metastatic cervical cancer covers this stage honestly.
The broad pattern is consistent across every registry: the more localised the disease when it is found, the better the outlook, and the difference between the earliest and the latest stages is large. That is the single most useful thing survival data tells us — and it is an argument for screening, not a verdict on anyone.
What Moves the Outlook Within the Same Stage
Two women can share a stage and still sit at opposite ends of its range. These are the factors that separate them, and every one of them is recorded somewhere in your notes.
Lymph node status
Whether cancer is found in the pelvic or para-aortic nodes is the most powerful modifier after stage itself. Since the 2018 revision it is built into the stage as IIIC, but the number of nodes involved and where they sit still shapes the plan and the outlook.
Tumour size and depth of invasion
A four-centimetre tumour and a one-centimetre tumour can both be stage IB. They do not behave the same way, they are not always treated the same way, and the difference between them is visible on your MRI report.
Histological subtype
Squamous cell carcinoma is the commonest type. Adenocarcinoma and adenosquamous carcinoma can behave differently, and the rare neuroendocrine subtypes are managed as a distinct entity altogether. The subtype is on your biopsy report.
Whether treatment is completed as planned
For chemoradiation, the total elapsed time from the first fraction to the last matters. Unplanned gaps, or substituting external radiation for brachytherapy, are associated with poorer disease control — which is one reason outcomes vary between centres treating identical stages.
Your general health, age and anaemia
Fitness to receive the full planned treatment is itself a prognostic factor. Correcting anaemia, controlling diabetes and maintaining nutrition through chemoradiation are not side issues — they are part of why some women complete treatment on schedule and others do not.
Where to take this next: each of these factors is unpacked further in our guide to what affects cervical cancer prognosis. And because the question behind “what is my survival rate” is usually “will it come back”, our pillar guide to cervical cancer recurrence, its risk factors and monitoring answers that question directly.
12+ Centres in Hyderabad · Pick yours
CION cancer care is closer than you think.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centre
Beyond Hyderabad
35+ centres across Telangana & Andhra Pradesh
Travelling for treatment? We may have a centre right where you are.
Telangana
Andhra Pradesh
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
A Percentage Cannot Read Your Scans. An Oncologist Can.
Bring your MRI, your PET-CT and your biopsy report. In 45 minutes you can find out what your stage means in your case, and what the treatment plan would be.
How to Read Any Survival Figure You Find Online
You will find numbers elsewhere, and there is nothing wrong with looking. There is a way to look that leaves you better informed rather than more frightened.
Step 1 — Check which staging system the figure uses
Ask whether the source is using FIGO 2018 or an earlier version, and whether it is grouping by FIGO stage or by the broader “localised / regional / distant” categories that cancer registries often use. These are not interchangeable, and a figure quoted against the wrong system is simply the wrong figure.
Step 2 — Check when the women in it were treated
Look for the diagnosis years, not the publication year. A statistic published this year may describe women diagnosed a decade ago, before routine PET-CT staging and before image-guided brachytherapy became standard practice in good centres.
Step 3 — Check the population
Survival differs between countries mainly because the stage mix at diagnosis differs. Where screening is widespread, more cancers are found early and overall survival looks better — that is a statement about screening coverage, not about the biology of the disease or the skill of the doctors.
Step 4 — Look for a range, not a point
A responsible source gives a confidence interval or a range. A single decimal-point figure applied to an individual woman is a misuse of the data, whoever is quoting it.
Step 5 — Then bring it to your oncologist
Print it, bring it, and ask directly: “does this apply to me, and if not, why not?” A good oncologist will not be irritated by the question. At CION every case is discussed at a multidisciplinary tumour board, in line with NCCN, FIGO and ESMO guidance, and you are entitled to know what that discussion concluded about your own outlook.
The Questions That Get You a Real Answer
“What are my chances?” is hard for any oncologist to answer usefully. These questions are answerable, and between them they give you the same information — grounded in your case rather than in a table.
| Ask this | Why it is a better question | What you learn |
|---|---|---|
| What is my exact FIGO stage, and what decided it? | Forces the specific finding — size, parametrium, nodes — into the open | Whether you sit at the favourable or unfavourable end of your stage |
| Are my lymph nodes involved, and how many? | Node status is the strongest modifier after stage | Whether radiation fields and systemic treatment need to be wider |
| Is the treatment being given with the intent to control the disease? | Separates disease-directed intent from symptom-directed care, without demanding a promise | The honest goal of the plan, in the team’s own words |
| How many days will my whole radiation course take? | Overall treatment time affects disease control | Whether the centre is planning to finish on schedule, brachytherapy included |
| What would change the plan, and when would you know? | Turns an unknowable forecast into a set of decision points | What is being watched, and what the alternatives are |
| What does my follow-up schedule look like? | Recurrence risk is concentrated in the first two to three years | How the plan continues after treatment ends, in writing |
Every one of these questions can be put to a CION oncologist at a free first consultation, and the modalities behind the answers — surgery, chemoradiation, brachytherapy and systemic therapy — are described on our cervical cancer treatment in Hyderabad page. If you are still finding your bearings, the cervical cancer overview is the place to start.
Did You Know? Survival statistics are not fixed properties of a stage — where a woman is treated shows up in them. CION's cervical cancer patients record a 1-year survival of 83.3%, against a national figure of 67.3%. The difference comes from unglamorous things: completing radiation within the planned overall time, finishing brachytherapy rather than substituting it, and putting every case through a multidisciplinary tumour board before treatment starts. Sources: CION Cancer Clinics outcomes data; national comparator, ICMR-NCDIR National Cancer Registry Programme.
Why Women in Hyderabad Bring Their Staging to CION
A stage is only as good as the assessment behind it — and only as useful as the explanation you are given.
Staging confirmed before treatment
Tumour board for every case
Radiation completed on schedule
Brachytherapy done, not substituted
45-minute detailed consultation
Woman doctor available on request
7 NABH-accredited Hyderabad locations
EMI facility & insurance accepted
4.8 / 5 Google rating
Take The Next Step
You Are Not a Statistic, and You Deserve to Be Told So Properly
The most useful hour you can spend right now is not on a search engine. It is with someone who has your scans open in front of them.
Real Stories. Real Voices.
15,000+ patients chose CION. Hear from them directly.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
4.8★800+ Google reviews
50+video testimonials
15,000+patients treated
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.
Common questions
Cervical Cancer Survival by Stage — Frequently Asked Questions
What does a five-year survival rate actually measure?
It measures the proportion of a large group of women, diagnosed at a given stage some years ago, who were still alive five years after diagnosis. Three things follow. It is historical, because a five-year figure needs women diagnosed at least five years ago, treated with the imaging and radiation technique of that time. It is an average across a wide range of tumour sizes and node findings within the same stage. And five years is a measuring post chosen because most recurrences appear before it — it is not a statement that survivors have five years to live.
Why will my oncologist not give me a single percentage?
Because a percentage drawn from a registry describes a group, and your oncologist is looking at one woman with a specific tumour size, node status, subtype, haemoglobin and set of other conditions. Applying the group figure to you would give an impression of precision the data cannot support, in either direction — it can frighten a woman whose case is favourable and falsely reassure one whose case is not. What a good oncologist will do instead is tell you the intent of the treatment, what specifically in your reports is favourable or unfavourable, and what would change the plan.
Do survival figures published overseas apply to women in India?
Only loosely, and mostly because the mix of stages at diagnosis differs. In countries with long-established screening programmes, a larger share of cervical cancers are found while still confined to the cervix, so the overall survival figure looks better. That is a statement about screening coverage rather than about biology or about the quality of treatment. When comparing sources, look at survival within a single stage rather than overall survival, and check which version of FIGO staging is being used, since the 2018 revision moved node-positive women into stage IIIC.
My stage changed after surgery. Which one counts?
The FIGO stage assigned at diagnosis is the one that stays in your record and the one that survival tables are grouped by; it is not revised upward or downward later. What surgery adds is pathological detail — the true tumour size, the depth of invasion, whether lymphovascular space invasion was seen, the margin status and how many nodes contained cancer. That detail can change your treatment, for example by adding radiation after an operation, and it is often more informative about your individual outlook than the stage label itself. Ask for the histopathology report and have it explained.
Does the type of cervical cancer matter as much as the stage?
Stage remains the strongest single influence, but subtype is not irrelevant. Squamous cell carcinoma is the commonest type and the one most of the published data describes. Adenocarcinoma and adenosquamous carcinoma can behave differently and are sometimes less easily detected by cytology-based screening. The rare neuroendocrine and small cell subtypes are managed as a distinct entity with a different systemic approach from the outset. Your biopsy report names the subtype, and it is a reasonable thing to ask your oncologist to explain, because it does influence how closely you are followed afterwards.
Medical disclaimer: This page is general health information, reviewed by a CION oncologist. It explains how survival statistics are constructed and how to interpret them; it is not a prognosis and cannot predict any individual outcome. Survival depends on your stage, pathology, general health and the treatment you receive. Please discuss your own outlook with your treating oncologist rather than relying on any website.